Intercept Pharmaceuticals Inc., of New York, recorded $40.9 million in worldwide net sales of Ocaliva (obeticholic acid), including a change in estimate related to deferred revenue with a net effect of a one-time increase of $4.1 million in net revenue for the third quarter.